-
Add to Cart The item has been addedS651962-5mg(Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor , and has the potential of reducing the secretion of gastric acid.In Vitro(Rac)-Sograzepide is an antagonist of CCK-B receptor, and has the potential of reducing the secretion -
Add to Cart The item has been addedS656898-1ml(Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor , and has the potential of reducing the secretion of gastric acid.In Vitro(Rac)-Sograzepide is an antagonist of CCK-B receptor, and has the potential of reducing the secretion -
Add to Cart The item has been addedW649483-10mg(Rac)-WAY-161503 is a potent, selective, highly affinity 5-HT 2C receptor agonist with a K i of 4 nM and an EC 50 of 12 nM. (Rac)-WAY-161503 displays higher affinity for 5-HT 2C than 5-HT 2A and 5-HT 2B receptors. (Rac)-WAY-161503 has anti-obesity -
Add to Cart The item has been addedW649483-5mg(Rac)-WAY-161503 is a potent, selective, highly affinity 5-HT 2C receptor agonist with a K i of 4 nM and an EC 50 of 12 nM. (Rac)-WAY-161503 displays higher affinity for 5-HT 2C than 5-HT 2A and 5-HT 2B receptors. (Rac)-WAY-161503 has anti-obesity -
Add to Cart The item has been addedW655879-1ml(Rac)-WAY-161503 is a potent, selective, highly affinity 5-HT 2C receptor agonist with a K i of 4 nM and an EC 50 of 12 nM. (Rac)-WAY-161503 displays higher affinity for 5-HT 2C than 5-HT 2A and 5-HT 2B receptors. (Rac)-WAY-161503 has anti-obesity -
Add to Cart The item has been addedZ647219-10mg(Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a cannabinoid receptor type 1 (CB 1 R)/iNOS antagonist, with a K i of 5.7 nM for CB 1 R. (Rac)-Zevaquenabant is potential for the research of liver fibrosisForm:SolidIC50&: Target:CB 1 R/iNOS. -
Add to Cart The item has been addedZ647219-25mg(Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a cannabinoid receptor type 1 (CB 1 R)/iNOS antagonist, with a K i of 5.7 nM for CB 1 R. (Rac)-Zevaquenabant is potential for the research of liver fibrosisForm:SolidIC50&: Target:CB 1 R/iNOS. -
Add to Cart The item has been addedZ647219-5mg(Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a cannabinoid receptor type 1 (CB 1 R)/iNOS antagonist, with a K i of 5.7 nM for CB 1 R. (Rac)-Zevaquenabant is potential for the research of liver fibrosisForm:SolidIC50&: Target:CB 1 R/iNOS. -
Add to Cart The item has been addedZ654926-1ml(Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a cannabinoid receptor type 1 (CB 1 R)/iNOS antagonist, with a K i of 5.7 nM for CB 1 R. (Rac)-Zevaquenabant is potential for the research of liver fibrosisIC50&: Target:CB 1 R/iNOS. -
Add to Cart The item has been addedP661596-1ml(rel)-PROTAC ERRα Degrader-1 is a relative configuration of PROTAC ERRα Degrader-1. PROTAC ERRα Degrader-1 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha ( ERRa ) binding group. PROTAC ERRα Degrader-1 is an -
Add to Cart The item has been addedR658774-10mg(rel)-PROTAC ERRα Degrader-1 is a relative configuration of PROTAC ERRα Degrader-1. PROTAC ERRα Degrader-1 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha ( ERRa ) binding group. PROTAC ERRα Degrader-1 is an -
Add to Cart The item has been addedR658774-1mg(rel)-PROTAC ERRα Degrader-1 is a relative configuration of PROTAC ERRα Degrader-1. PROTAC ERRα Degrader-1 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha ( ERRa ) binding group. PROTAC ERRα Degrader-1 is an
